$NVRO News
Last published 1y ago
- 1y agoNVROGMEDNevro Reports Fourth-Quarter and Full-Year 2024 Financial ResultsPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 1y agoNVROSLRNTGIPTMNKuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 1y agoGMEDNVROGlobus Medical to Acquire Nevro Corp. to Expand Treatment Options for PatientsGlobeNewswireAUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is
- 1y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 1y agoNVRONevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue ResultsPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 1y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 1y agoNVRONew Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral ApproachesPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 1y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 1y agoNVRONevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion GloballyPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Corp. (NVRO) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoNVRONevro Reports Third-Quarter 2024 Financial ResultsPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONew Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation TherapyPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today...
- 2y agoNVRONevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord StimulationPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Present at Wells Fargo 2024 Healthcare ConferencePR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Corp. - Appeal, ReversedUS Patent Trial and Appeal Board
- 2y agoNVRONevro Corp. (NVRO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoNVRONevro Reports Second-Quarter 2024 Financial ResultsPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today...
- 2y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Present at Truist Securities MedTech ConferencePR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Present at BofA Securities 2024 Healthcare ConferencePR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Corp. (NVRO) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoNVRONevro Reports First-Quarter 2024 Financial ResultsPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today...
- 2y agoNVRONevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today...
- 2y agoNVRONevro Corp. (NVRO) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoNVRONevro Enters Into Cooperation Agreement With Engaged CapitalPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsPR Newswireevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, ...
- 2y agoNVRONevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic NeuropathyPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024PR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic NeuropathyPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual MeetingPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today...
- 2y agoNVRONevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue ResultsPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro to Present at 42nd Annual J.P. Morgan Healthcare ConferencePR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Announces Acquisition of Vyrsa™ TechnologiesPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 2y agoNVRONevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back PainPR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 3y agoNVRONevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 GuidancePR NewswireNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
- 3y agoNVRONevro to Report Third Quarter 2023 Financial ResultsPR NewswireCompany to Host Conference Call on Wednesday, November 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., Oct. 4, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering
- 3y agoNVRONew Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation TherapyPR NewswirePublications Show Reductions in Hospital Resource Utilization Associated with 10 kHz Therapy Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back Pain REDWOOD CITY,
- 3y agoNVRONevro Announces Participation in Upcoming Investor ConferencesPR NewswireREDWOOD CITY, Calif., Aug. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it
- 3y agoNVRONew 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic NeuropathyPR NewswireEvidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep REDWOOD CITY, Calif., Aug. 16, 2023 /PRNewswire/ --
- 3y agoNVRONevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 GuidancePR NewswireCompany Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Opportunities REDWOOD CITY, Calif., Aug. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is
- 3y agoNVRONevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual ConferencePR NewswireAbstract Presentations Highlight Durable Pain Relief and Improved Quality of Life for Patients Receiving 10 kHz Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy and Non-Surgical Back Pain Symposium on the
- 3y agoNVRONevro to Present at the Canaccord Genuity 43rd Annual Growth ConferencePR NewswireWednesday, August 9, 2023 at 8:30 am Eastern Time REDWOOD CITY, Calif., July 12, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for